Viking Therapeutics Inc. (NASDAQ:VKTX) stock went on an upward path that rose over 2.25%, amounting to a one-week price increase of more than 2.09%. Over the last 12 months, VKTX stock dropped by -23.86%. The one-year VKTX stock forecast points to a potential downside of -2.47, with the average price target set at $23.73 per share. The average equity rating for VKTX stock is currently 1.50, trading closer to a bullish pattern in the stock market.
The market cap for VKTX stock reached $504.05 million, with 73.80 million shares outstanding and 64.29 million shares in the current float. Compared to the average trading volume of 1.26M shares, VKTX reached a trading volume of 841822 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Viking Therapeutics Inc. (VKTX):
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VKTX shares is $23.70 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VKTX stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for Viking Therapeutics Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on July 16, 2019. The new note on the price target was released on June 25, 2019, representing the official price target for Viking Therapeutics Inc. stock. Previously, the target price had yet another raise from $10 to $21, while SVB Leerink kept a Outperform rating on VKTX stock. On March 14, 2019, analysts decreased their price target for VKTX shares from 28 to 20.
The Price to Book ratio for the last quarter was 1.73, with the Price to Cash per share for the same quarter was set at 3.90. Quick ratio for the last quarter at 46.70.
VKTX Stock Performance Analysis:
Viking Therapeutics Inc. (VKTX) gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.09. With this latest performance, VKTX shares dropped by -6.44% in over the last four-week period, additionally sinking by -2.84% over the last 6 months – not to mention a drop of -23.86% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VKTX stock in for the last two-week period is set at 47.66, with the RSI for the last a single of trading hit 53.58, and the three-weeks RSI is set at 46.34 for Viking Therapeutics Inc. (VKTX). The present Moving Average for the last 50 days of trading for this stock 7.35, while it was recorded at 6.70 for the last single week of trading, and 7.48 for the last 200 days.
Insight into Viking Therapeutics Inc. Fundamentals:
Return on Total Capital for VKTX is now -16.63, given the latest momentum, and Return on Invested Capital for the company is -14.18. Return on Equity for this stock declined to -14.18, with Return on Assets sitting at -13.60.
Reflecting on the efficiency of the workforce at the company, Viking Therapeutics Inc. (VKTX) managed to generate an average of -$1,470,867 per employee. Viking Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 46.70 and a Current Ratio set at 46.70.
VKTX Stock EPS
With the latest financial reports released by the company, Viking Therapeutics Inc. posted -0.07/share EPS, while the average EPS was predicted by analysts to be reported at -0.1/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 30.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for VKTX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Viking Therapeutics Inc. go to 40.00%.
Viking Therapeutics Inc. (VKTX) Insider Position Details
There are presently around $264 million, or 57.60% of VKTX stock, in the hands of institutional investors. The top three institutional holders of VKTX stocks are: ARROWMARK COLORADO HOLDINGS LLC with ownership of 8,131,528, which is approximately 18.69% of the company’s market cap and around 2.50% of the total institutional ownership; BLACKROCK INC., holding 4,495,717 shares of the stock with an approximate value of $30.03 million in VKTX stocks shares; and STATE STREET CORP, currently with $24.12 million in VKTX stock with ownership of nearly -6.491% of the company’s market capitalization.
Positions in Viking Therapeutics Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 60 institutional holders increased their position in Viking Therapeutics Inc. (NASDAQ:VKTX) by around 3,364,140 shares. Additionally, 67 investors decreased positions by around 6,287,905 shares, while 40 investors held positions by with 29,842,972 shares. The mentioned changes placed institutional holdings at 39,495,017 shares, according to the latest SEC report filing. VKTX stock had 13 new institutional investments in for a total of 670,086 shares, while 25 institutional investors sold positions of 2,722,107 shares during the same period.